Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$27.55−0.49 (-1.75%)
Close on Nov 18, 2026Market cap $2.16BP/E –Yield –
Celldex Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Celldex Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$242.11M. For fiscal 2025 it was -$213.66M. The highest annual figure on record is -$30.40M in fiscal 2009.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$213.66M | – |
| FY2024 | Dec 31, 2024 | -$159.70M | – |
| FY2023 | Dec 31, 2023 | -$109.11M | – |
| FY2022 | Dec 31, 2022 | -$105.56M | – |
| FY2021 | Dec 31, 2021 | -$62.16M | – |
| FY2020 | Dec 31, 2020 | -$41.96M | – |
| FY2019 | Dec 31, 2019 | -$47.15M | – |
| FY2018 | Dec 31, 2018 | -$76.05M | – |
| FY2017 | Dec 31, 2017 | -$101.72M | – |
| FY2016 | Dec 31, 2016 | -$115.79M | – |
| FY2015 | Dec 31, 2015 | -$103.76M | – |
| FY2014 | Dec 31, 2014 | -$103.47M | – |
| FY2013 | Dec 31, 2013 | -$71.89M | – |
| FY2012 | Dec 31, 2012 | -$50.09M | – |
| FY2011 | Dec 31, 2011 | -$36.17M | – |
| FY2010 | Dec 31, 2010 | -$32.47M | – |
| FY2009 | Dec 31, 2009 | -$30.40M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$60.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$67.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$65.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$49.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.64M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$40.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$33.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.07M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.65M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.46M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.35M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.11M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.45M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.73M | – |
| Q1 FY2018 | Mar 31, 2018 | -$28.28M | – |
| Q4 FY2017 | Dec 31, 2017 | -$19.71M | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.64M | – |
| Q2 FY2017 | Jun 30, 2017 | -$21.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$35.64M | – |
| Q4 FY2016 | Dec 31, 2016 | -$20.99M | – |
| Q3 FY2016 | Sep 30, 2016 | -$24.76M | – |
See a number that looks wrong?